Key facts
- This page summarizes Michael Skynner's Form 4 filing for BICYCLE THERAPEUTICS PLC (BCYC).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 04 Apr 2025, 17:35.
Michael Skynner - 02 Apr 2025 Form 4 Insider Report for BICYCLE THERAPEUTICS PLC (BCYC)
- Reporting relationship
- CHIEF TECHNOLOGY OFFICER
- Issuer ticker
- BCYC
- Reported as of
- 02 Apr 2025
- Net transaction value
- -$14,293
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2025, 17:35:11 UTC
- Prior SEC filing
- 06 Jan 2025
- Next SEC filing
- 07 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason Minio, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Skynner filed Form 4 for BICYCLE THERAPEUTICS PLC (BCYC) on 04 Apr 2025.
Change
- Previous filing in this sequence was filed on 06 Jan 2025.
- Current net transaction value: -$14,293.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCYC
transaction
Ordinary Shares
Sale
- Transaction value
- $6,528
- Shares
- -814
- Change %
- -0.66%
- Price
- $8.02
- Shares after
- 122,908
- Date
- 02 Apr 2025
- Ownership
- Direct
- Footnotes
- F1, F2
BCYC
transaction
Ordinary Shares
Sale
- Transaction value
- $7,764
- Shares
- -1,038
- Change %
- -0.84%
- Price
- $7.48
- Shares after
- 121,870
- Date
- 03 Apr 2025
- Ownership
- Direct
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.43 to $7.50 inclusive.